设为首页收藏本站

中国病毒学论坛|我们一直在坚持!

 找回密码
 立即注册

QQ登录

只需一步,快速开始

搜索
热搜: 活动 交友 discuz
查看: 982|回复: 1
打印 上一主题 下一主题

nature上关于慢性乙型肝炎的综述

[复制链接]

6

帖子

105

学分

529

金币

病毒学院大学生

Rank: 4Rank: 4Rank: 4Rank: 4

积分
105
跳转到指定楼层
楼主
发表于 2015-9-1 17:42:33 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式
nature上关于慢性乙型肝炎的综述


本帖子中包含更多资源

您需要 登录 才可以下载或查看,没有帐号?立即注册

x

评分

参与人数 1学分 +28 收起 理由
bigben446 + 28

查看全部评分

分享到:  QQ好友和群QQ好友和群 QQ空间QQ空间 腾讯微博腾讯微博 腾讯朋友腾讯朋友
收藏收藏 分享分享 支持支持 反对反对

119

帖子

57

学分

799

金币

VIP荣誉会员

Rank: 9Rank: 9Rank: 9Rank: 9

积分
57
沙发
发表于 2015-9-1 20:50:05 | 只看该作者
【标题】:Hepatitis B therapy
【作者】:Kwon, H.; Lok, A. S.
【来源】:Nat Rev Gastroenterol Hepatol, 2011, 8(5), 275-284
【摘要】:The goal of hepatitis B treatment is to prevent cirrhosis, liver decompensation and hepatocellular carcinoma. In clinical practice, treatment response is determined by suppression of serum HBV DNA levels, hepatitis B e antigen seroconversion to hepatitis B e antibody, hepatitis B surface antigen loss, normalization of alanine aminotransferase levels and improvement in liver histology. Patients with life-threatening liver disease, and those with high levels of HBV replication and active or advanced liver disease, should be treated. Other patients should be monitored so that treatment can be initiated when indicated. Currently, seven medications are approved for the treatment of hepatitis B: two formulations of interferon and five nucleos(t)ide analogues. Interferon is administered for a finite duration while nucleos(t)ide analogues are usually administered for many years. Antiviral drug resistance is a major limiting factor to the success of nucleos(t)ide analogue treatment; therefore, treatment should be initiated with drugs that have a high genetic barrier to resistance (that is, a low potential for drug resistance). In addition, treatment response should be closely monitored to detect virologic breakthroughs, and the importance of medication adherence should be emphasized. Management of patients with treatment failure should be tailored according to the type of treatment failure (lack of initial response versus virologic breakthrough), the treatment that the patient is receiving, history of prior treatment, and the pretreatment characteristics of both the patient and the disease.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

QQ|论坛App下载|Archiver|小黑屋|中国病毒学论坛    

GMT+8, 2024-11-5 23:36 , Processed in 0.130241 second(s), 30 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表